About: Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical Trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical Trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical Trial
Creator	Tabarsi, Payam Marjani, Majid Moniri, Afshin Varahram, Mohammad Mohammad, Seyed Abedini, A Abedini, Atefeh Dastan, Farzaneh Dastan, F Haseli, Sara Haseli, S Kiani, Arda Kiani, A Marjani, M Moniri, A Nadji, Alireza Nadji, S Saffaei, Ali Saffaei, A Shiva, P Shiva, Parvaneh Varahram, M Yousefian, S Yousefian, Sahar Hashemian, Reza Abtahian, Zahra Abtahian, Z Dastan, Dastan, A Dastan, Alireza Eslaminejad, A Eslaminejad, Alireza Gallo, Julio Heshmatnia, J Heshmatnia, Jalal Jammati, H Jammati, Hamidreza Mohammad, S Poorabdollah, M Poorabdollah, Mihan Program, Management Sadeghi, M Sadeghi, Mohsen Salamzadeh, J Salamzadeh, Jamshid Seifi, S Seifi, Sharareh Trial, Farzaneh
Source	Elsevier; PMC
abstract	BACKGROUND: The clinical presentation of SARS-CoV-2 infection ranges from mild symptoms to severe complications, including acute respiratory distress syndrome. In this syndrome, inflammatory cytokines are released after activation of the inflammatory cascade, with the predominant role of interleukin (IL)-6. The aim of this study was to evaluate the effects of tocilizumab, as an IL-6 antagonist, in patients with severe or critical SARS-CoV-2 infection. METHODS: In this prospective clinical trial, 76 patients with severe or critical SARS-CoV-2 infection were evaluated for eligibility, and ultimately, 42 patients were included. Tocilizumab was administered at a dose of 400 mg as a single dose via intravenous infusion. Primary outcomes included changes in oxygenation support, need for invasive mechanical ventilation, and death. Secondary outcomes included radiological changes in the lungs, IL-6 plasma levels, C-reactive protein levels, and adverse drug reactions. The data were analyzed using SPSS software. RESULTS: Of the 42 included patients, 20 (48%) patients presented the severe infection stage and 22 (52%) were in the critical stage. The median age of patients was 56 years, and the median IL-6 level was 28.55 pg/mL. After tocilizumab administration, only 6 patients (14%) required invasive ventilation. Additionally, 35 patients (83.33%) showed clinical improvement. By day 28, a total of 7 patients died (6 patients in the critical stage and 1 patient in the severe stage). Neurological adverse effects were observed in 3 patients. CONCLUSIONS: Based on the current results, tocilizumab may be a promising agent for patients with severe or critical SARS-CoV-2 infection, if promptly initiated during the severe stage.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1016/j.intimp.2020.106869
has license	no-cc
sha1sum (hex)	026c5b60a7594c352c6ff272154ab88a1e55a0a3
schema:url	https://doi.org/10.1016/j.intimp.2020.106869
resource representing a document's title	Promising Effects of Tocilizumab in COVID-19: A Non-Controlled, Prospective Clinical Trial
has PubMed Central identifier	PMC7402206
schema:publication	Int Immunopharmacol
resource representing a document's body	covid:026c5b60a7594c352c6ff272154ab88a1e55a0a3#body_text
is schema:about of	named entity 'Highlights' named entity 'COVID-19' named entity 'Tocilizumab' named entity 'adverse effects' named entity 'adverse drug reactions' named entity 'Social Sciences' named entity 'invasive mechanical ventilation' named entity 'platelet count' named entity 'interleukin-6' named entity 'methylprednisolone' named entity 'IL-6' named entity 'informed consent' named entity 'Lung' named entity 'COVID' named entity 'T-cell' named entity '28 days' named entity 'serum' named entity 'survival rate' named entity 'tocilizumab' named entity '8.5' named entity 'tocilizumab' named entity 'invasive mechanical ventilation' named entity 'invasive ventilation' named entity 'Tocilizumab' named entity 'mortality rate' named entity 'ICU' named entity 'invasive mechanical ventilation' named entity 'Wuhan' named entity 'lopinavir/ritonavir' named entity 'infection' named entity 'infection' named entity 'inflammatory cascade' named entity 'latent tuberculosis' named entity 'Hoffmann-La Roche' named entity 'adverse effect' named entity 'ANC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software